Guilin Sanjin Pharmaceutical Co. Ltd, a Chinese pharmaceutical company listed on the Shenzhen Stock Exchange (SHE: 002275), has announced that its subsidiary, Dragon Boat Pharmaceutical (Shanghai) Co., Ltd, has obtained approval from the National Medical Products Administration (NMPA) to initiate a Phase I clinical study for its drug candidate BC011, intended for the treatment of advanced solid tumors.
The drug candidate, a monoclonal antibody (mAb), is designed with antibody-dependent cellular cytotoxicity (ADCC) activity. BC011 has the potential to reduce regulatory T cells (Treg), enhance the tumor-killing activity of CD8+ T cells, and directly target tumor cells for destruction. In vitro pharmacological studies have demonstrated that BC011 exhibits high specificity, effectively inhibiting the infiltration of tumor cells into Treg cells. This action increases the proportion and quantity of cytotoxic T lymphocyte (CTL) infiltration, leading to an elevated CTL/Treg ratio, which is instrumental in modulating the tumor immune microenvironment and is indicative of its robust anti-tumor capabilities and favorable safety profile.- Flcube.com
